South Med J. 2005 Jun;98(6):628-35.

Treatments for Alzheimer disease.

Source

Internal Medicine Residency Spokane, University of Washington School of Medicine, Spokane, WA 99210, USA. potykd@empirehealth.org

Abstract

As our population ages, the incidence and prevalence of Alzheimer disease (AD) will increase dramatically. A number of therapies have been investigated for the treatment and prevention of AD. Clinicians should be prepared to provide evidence-based answers to inquiries regarding AD treatment. There is insufficient evidence to recommend ginkgo biloba, estrogen, statins, or nonsteroidal anti-inflammatory drugs for the prevention or treatment of AD. The use of vitamin E is supported by a single randomized controlled trial, while data on other antioxidants is mixed. There is good evidence that cholinesterase inhibitors and memantine are modestly effective in the treatment of AD. Cholinesterase inhibitors appear to be effective throughout the spectrum of AD, while memantine, alone or in combination with cholinesterase inhibitors, is effective in late stage disease. There is insufficient evidence to suggest superiority of one cholinesterase over another.

Comment in

South Med J. 2005 Jun;98(6):588-9.

PMID:: 16004170; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Review Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. [J Psychopharmacol. 2006]
Review Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns A, O'Brien J, BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, et al. J Psychopharmacol. 2006 Nov; 20(6):732-55.
Review Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies. [J Clin Psychiatry. 2006]
Review Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN. J Clin Psychiatry. 2006; 67 Suppl 3:15-22; quiz 23.
Treatment of Alzheimer's disease: current status and new perspectives. [Lancet Neurol. 2003]
Treatment of Alzheimer's disease: current status and new perspectives.
Scarpini E, Scheltens P, Feldman H. Lancet Neurol. 2003 Sep; 2(9):539-47.
Review Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. [Dement Geriatr Cogn Disord. 2008]
Review Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.
Farlow MR, Miller ML, Pejovic V. Dement Geriatr Cogn Disord. 2008; 25(5):408-22. Epub 2008 Apr 3.
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. [Curr Alzheimer Res. 2008]
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.

See reviews... See all...

Cited by 2 PubMed Central articles

Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. [J Biomed Biotechnol. 2006]
Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease.
Rojo L, Sjöberg MK, Hernández P, Zambrano C, Maccioni RB. J Biomed Biotechnol. 2006; 2006(3):73976.
Review Treatment of dementia. [J Neurol Neurosurg Psychiatry. 2005]
Review Treatment of dementia.
Overshott R, Burns A. J Neurol Neurosurg Psychiatry. 2005 Dec; 76 Suppl 5:v53-9.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treatments for Alzheimer disease.
Treatments for Alzheimer disease.
South Med J. 2005 Jun ;98(6):628-35.

PubMed
Current epidemiology of mild cognitive impairment and other predementia syndrome...
Current epidemiology of mild cognitive impairment and other predementia syndromes.
Am J Geriatr Psychiatry. 2005 Aug ;13(8):633-44.

PubMed
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's...
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
Science. 1994 Mar 4 ;263(5151):1281-4.

PubMed
IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette s...
IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette smoke in mouse lung.
Am J Respir Cell Mol Biol. 2008 Jun ;38(6):689-98. Epub 2008 Jan 31 .

PubMed
Differential loss of cytochrome-c oxidase subunits in ischemia-reperfusion injur...
Differential loss of cytochrome-c oxidase subunits in ischemia-reperfusion injury: exacerbation of COI subunit loss by PKC-epsilon inhibition.
Am J Physiol Heart Circ Physiol. 2008 Jun ;294(6):H2637-45. Epub 2008 Apr 11 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: